Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Capital Expenditures came in at $663000.0 in Q2 2026, up 847.14% YoY from $70000.0 in Q2 2025, and up 311.8% on a QoQ basis from $161000.0 in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Capital Expenditures data on file, last reported at $663000.0 in Q2 2026.
- Quarterly Capital Expenditures rose 847.14% year-over-year to $663000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.4 million (up 681.22% YoY) and the FY2025 annual result came in at $1.6 million, down 83.89% from the prior year.
- Capital Expenditures advanced to $663000.0 in Q2 2026, from $161000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $3.8 million in Q2 2024 to a low of -$3.3 million in Q1 2023.
- A 5-year average of $287588.2 and a median of $90000.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures plunged 1292.64% — and 2024, when it jumped 4165.56%.
- Tracing KNSA's Capital Expenditures over 5 years: stood at $265000.0 in 2022, then slumped by 630.57% to -$1.4 million in 2023, then soared by 279.52% to $2.5 million in 2024, then soared by 34.71% to $3.4 million in 2025, then slumped by 80.5% to $663000.0 in 2026.
- The last three Capital Expenditures figures came in at $663000.0 (Q2 2026), $161000.0 (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn | 663,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 663,000.00 |
| Jun 30, 2026 | 663,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Dec 31, 2025 | 3.40 Mn |
| Dec 31, 2025 | 3.40 Mn |
| Sep 30, 2025 | 143,000.00 |
| Sep 30, 2025 | 143,000.00 |
| Jun 30, 2025 | 70,000.00 |
| Jun 30, 2025 | 70,000.00 |
| Mar 31, 2025 | -2.05 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 3.36 Mn |
| Mar 31, 2024 | 3.36 Mn |